Intelligent Bio Solutions Prices Private Placement Expected to Bring About $5.0m at Closing; the Balance Rests on Two Warrant Series, Neither Yet Exercisable in Full

by Jonas Halvorsen · September 2, 2026

Companies Reporter, The MicroCap Herald

Intelligent Bio Solutions Inc. (Nasdaq: INBS) announced on Sept. 1, 2026 that it had agreed a private placement with a single existing institutional investor, priced at-the-market under Nasdaq rules. The company said gross proceeds at closing would be approximately $5.0m before placement agent fees and offering expenses, and that closing was expected on or about Sept. 2, 2026. As of the time of writing the transaction is an announced pricing rather than a completed funding, and the Herald did not locate a company release confirming that closing had occurred.

The structure, as described in the company's release, is a unit deal. The investor is purchasing 2,036,659 shares of common stock, or Series M pre-funded warrants in lieu of shares, together with Series N-1 warrants to purchase up to 2,036,659 shares and Series N-2 warrants to purchase up to a further 2,036,659 shares. The combined purchase price is $2.455 per share and accompanying warrants. Both warrant series carry an exercise price of $2.33 per share, and both carry a five-year term running from the effectiveness of the resale registration statement.

The release's headline number is up to $15m. Only the approximately $5.0m is expected at closing. The balance would arrive only if the warrants are exercised for cash, and the two series sit on different footings. The Series N-1 warrants are exercisable immediately upon issuance, at the holder's election; what is conditional is the company's ability to force them, which the release ties to the company's public announcement, by widely disseminated press release, that it has received 510(k) clearance from the U.S. Food and Drug Administration permitting the commercial marketing and sale of its Intelligent Fingerprinting Drug Screening System. The Series N-2 warrants are not exercisable at all unless and until stockholders approve their exercise. No proceeds from either series are committed, scheduled or assured, and the company cannot compel either outcome on its own.

Where the FDA submission actually stands

The clearance referenced in the call provision has not been received, and the regulatory history behind it is longer than a single pending submission. Per StockTitan's summary of the company's annual report on Form 10-K, the company submitted a 510(k) premarket notification to the FDA for its IFP System in December 2024; the FDA responded with an Additional Information request in February 2025; the company responded and submitted additional information in August 2025; and the FDA then requested further new information that required the company to resubmit a new 510(k) notification. The Herald did not retrieve the primary 10-K, and that account is attributed to the named secondary source accordingly.

On the forward timing, StockTitan's report of the company's fiscal 2026 full-year results release of Aug. 19, 2026 carries the chief executive, Harry Simeonidis, saying that clinical data collection across the FDA 510(k) clinical study program had been completed, that analysis of the collected data was under way, and that the company remained on track for its FDA submission, which the release placed in the second half of calendar 2026. Those characterisations are the company's own and are reported here in indirect speech. Clearance is a subsequent regulatory decision on a timeline the company does not control, and readers should not treat the up-to-$15m figure as money committed, scheduled or probable.

Scale relative to the existing share count

The dilution is large relative to the company's size. Per StockTitan's summary of the annual report for the fiscal year ended June 30, 2026, there were 3,027,470 common shares issued and outstanding as of Aug. 18, 2026. The 2,036,659 shares being placed are equivalent to roughly two-thirds of that count. The two warrant series cover up to 2,036,659 shares each, so full exercise of both would add a further 4,073,318 shares on top. The Herald was not able to retrieve the primary registration or transaction documents from EDGAR, and relies here on the company's own release and on StockTitan's summaries, which are identified in the sources below.

One caveat cuts the other way on the immediate share count. Because the investor may take Series M pre-funded warrants instead of common stock, the number of shares actually issued at closing may be lower than 2,036,659, with the balance sitting as pre-funded warrants. The release does not state how the investor has elected to split the allocation, so the exact post-closing share count is not determinable from the documents reviewed.

Financial position behind the raise

The financial figures that follow cover the company's fiscal year ended June 30, 2026 and were published on Aug. 19, 2026. They are more than two months old, they predate this placement, and they do not reflect any subsequent trading, spending or financing. The Herald did not retrieve the primary results release or the primary 10-K, and takes these figures from StockTitan's summaries of both, identified in the sources below.

For that fiscal year the company reported revenue of $4,215,175, up 38% from $3,052,532, and gross margin of 48.63% against 40.85% a year earlier. Net loss attributable to the company was $12,430,975, wider than the $10,568,733 reported for the fiscal year ended June 30, 2025. StockTitan's summary describes the statements presented as GAAP consolidated financial statements; the Herald did not review an adjusted or non-GAAP earnings measure and does not present one here.

The annual report carried going-concern language. Per StockTitan's summary of that filing, the company disclosed substantial doubt about its ability to continue as a going concern for a period of at least one year from the date the consolidated financial statements were issued, and the filing reported cash and cash equivalents of $3,992,312. The primary 10-K document could not be retrieved for this article, and that disclosure is attributed to the named secondary source accordingly.

Ladenburg Thalmann & Co. Inc. is acting as placement agent. The company said net proceeds from the private placement are intended for working capital and general corporate purposes. It also said it had agreed to file an initial registration statement covering the resale of the shares no later than 15 calendar days following the date of the agreement, and to have that statement declared effective no later than 45 days after the date of the agreement.

Micro-cap and nano-cap securities carry substantial risk, including the possible total loss of an investment. Trading in these names is often thin, and a quoted price may not be obtainable in any meaningful size. Where a company has disclosed substantial doubt about its ability to continue as a going concern, that disclosure applies to the enterprise as a whole and is not cured by an announced financing.

The Herald does not offer investment advice, does not publish price targets, and takes no view on whether any security discussed here should be bought or sold. This article reports what the company and the filing summaries stated, and identifies where a stated figure depends on a condition that has not been satisfied.